Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Astrivax Therapeutics logo — Pioneering immune interventions to treat chronic disease

Astrivax Therapeutics

Pioneering immune interventions to treat chronic disease

Founded 2022 Belgium Belgium 31 employees Grant Total: $35.50M

General Information

Company Name Astrivax Therapeutics
Founded Year 2022
Location Belgium Belgium
Employees 31
Funding Stage Grant
Offices as of Sep 2026
Leuven, Belgium
Social

BounceWatch is an independent company data service, not affiliated with Astrivax Therapeutics. To contact Astrivax Therapeutics, visit astrivax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Sep 18, 2026

Astrivax Therapeutics' CEO, Hanne Callewaert, is joining the Belgian mission to Boston next week, a delegation focused on connecting innovators, investors, researchers, and industry leaders.

Get alerts when Astrivax Therapeutics shows new signals

About Astrivax Therapeutics

AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is committed to addressing real-world challenges in vaccinology by building a first-in-class Plug & Play vaccine platform with a patented DNA-based technology that launches self-amplifying live attenuated viruses. Their versatile technology can be used to develop a wide range of vaccines to prevent and treat infectious diseases. The company aims to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens. The Belgium-based startup recently received a €3.00M grant investment on 12 December 2023, with the investment coming from Agentschap Innoveren & Ondernemen. This investment will likely enable AstriVax to further advance their groundbreaking vaccine platform and potentially bring innovative vaccine solutions to market. With its promising technology and strategic partnerships, AstriVax is positioned to make significant contributions to the field of vaccinology.

Taxonomy: vaccinology, vaccine technology, DNA-based technology, live attenuated viruses, infectious diseases, vaccine development, cold chain requirements, broad-spectrum protection, pathogen prevention, clinical validation, vaccination pipeline

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €3.00M 1
Agentschap Innoveren & Ondernemen
12 Dec 2023
Grant €2.50M 1
Agentschap Innoveren & Ondernemen
30 May 2023
Seed Round €30.00M 8
Ackermans & van Haaren BNP Paribas Fortis Fund+
Ackermans & van Haaren, BNP Paribas Fortis +6
25 Aug 2022

Latest News

View All
The next wave of innovation: 10 promising Belgian startups to keep an eye on in 2025 — Eu-startups
The next wave of innovation: 10 promising Belgian startups to keep an eye on in 2025
Eu-startups Jan 07, 2025

Astrivax Therapeutics Alternatives & Competitors

View All Alternatives
Astrivax Therapeutics vs
GPN Vaccines
GPN Vaccines Australia

Developing innovative vaccines against the world's most important bacterial pathogens.

Series B
24 employees
Biotechnology
Astrivax Therapeutics vs
Rocketvax AG
Rocketvax AG Switzerland

Implementing cutting-edge science in next-generation vaccine design that will improve people’s lives...

Grant
6 employees
Biotechnology, Health Care
Astrivax Therapeutics vs
DIOSynVax
DIOSynVax United Kingdom

Innovation in Vaccine Antigen Design

Grant
22 employees
Biotechnology, Information Technology
View all alternatives

FAQ About Astrivax Therapeutics

Pioneering immune interventions to treat chronic disease
Astrivax Therapeutics was founded in 2022.
Astrivax Therapeutics is headquartered in Belgium. As of Sep 2026, it also has offices in Leuven, Belgium.
Astrivax Therapeutics has approximately 31 employees.
Astrivax Therapeutics has completed 3 funding rounds, raising a total of $35.50M. The latest funding stage is Grant.
Top alternatives and competitors to Astrivax Therapeutics include GPN Vaccines, Rocketvax AG, DIOSynVax, FLUGEN, INC., Novavax. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Astrivax Therapeutics and GPN Vaccines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Astrivax Therapeutics, https://bouncewatch.com/company/astrivax, updated 24 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes